Gilead inks pact on experimental RSV treatment

Gilead is throwing its considerable weight behind an RSV drug program now underway at MicroDose Therapeutx. Gilead will pay an undisclosed upfront and bankroll research work on MDT-637, an inhalable small molecule antiviral fusion inhibitor, through Phase IIa, when it will have to decide whether or not to pick up an option to take full responsibility for the treatment. "This strategic collaboration is a significant milestone in MicroDose's vision to develop first-in-class therapies for major unmet medical needs," said Anand Gumaste, the CEO of MicroDose. "Given Gilead's scientific and clinical expertise in virology, this partnership provides a strong validation of the potential for MDT-637 to become an important therapeutic advance for those affected by RSV infection." Gilead release

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.